EPO
Erythropoietin
Glycoprotein hormone made mainly by the kidney that binds the erythropoietin receptor on red-cell precursors, studied in erythropoiesis research.
Evidence level. Published human clinical data exists, from trials or approved use. About the badges
- Class
- Erythropoietin
- Category
- Reproductive & Endocrine
- Type
- Single compound
- Development and regulatory status
- Approved prescription drug (anaemia of chronic kidney disease and others)
What researchers study
Glycoprotein hormone made mainly by the kidney that binds the erythropoietin receptor on red-cell precursors, supporting their survival and maturation. Recombinant forms (epoetin) are used as erythropoiesis-stimulating agents.
Research areas
- Red-cell production and cell-culture studies
- Renal anaemia and EPO resistance research
- Cardiovascular risk of ESA therapy
- Long-acting EPO derivative comparisons
Reported findings
Summaries of published results. Each one is tagged with the type of study behind it. They describe research outcomes and are not claims about any product. Why study type matters.
- review
A 2026 review describes insufficient EPO production as the starting mechanism of renal anaemia, with inflammation and iron deficiency adding EPO resistance
- review
ESA therapy has been associated with a risk of cardiovascular events, particularly in hypo-responder patients
